Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Risk factors for rare diseases can be risky to define: PML and natalizumab.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Guillain-Barré syndrome: clinical profile and management.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Daclizumab (anti-CD25) in multiple sclerosis.
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.
Fingolimod modulates microglial activation to augment markers of remyelination.
Targeted Stage-Specific Inflammatory microRNA Profiling in Urine During Disease Progression in Experimental Autoimmune Encephalomyelitis: Markers of Disease Progression and Drug Response.
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
European Congress of Immunology 2012
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
Poor sleep in patients with multiple sclerosis.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.

Pages